Zoltán Kiss ^1,2* Tamás G. Szabó ¹ Csaba Polgár ^3,4 Zsolt Horváth ⁵ Péter Nagy ^6,7,8 Ibolya Fábián ^10,9 Valéria Kovács ⁹ György Surján ^11,12 Zsófia Barcza ¹³ István Kenessey ^14,15 András Wéber ¹⁴ István Wittmann ² Gergő A. Molnár ² Eszter Gyöngyösi ¹ Angéla Benedek ¹ Eugenia Karamousouli ¹ Zsolt Abonyi-Tóth ^10,9 Renáta Bertókné Tamás ¹¹ Diána V. Fürtös ¹¹ Krisztina Bogos ¹⁶ Judit Moldvay ^17,18 Gabriella Gálffy ¹⁹ Lilla Tamási ²⁰ Veronika Müller ²⁰ Zoárd Krasznai ²¹ Gyula Ostoros ¹⁶ Zsolt Pápai-Székely ²² Anikó Maráz ²³ Gabriella Branyiczkiné Géczy ²⁴ Lászlóné Hilbert ²⁴ László T. Berki ²⁵ György Rokszin ⁹ Zoltán Vokó ^25,26

• ¹ MSD Pharma Hungary Ltd., Budapest, Hungary
• ² University of Pécs II. Internal Medicine Clinic and Nephrology Center no, Pécs, Hungary
• ³ National Institute of Oncology and National Tumor Biology Laboratory, Budapest, Hungary
• ⁴ Department of Internal Medicine and Oncology, Faculty of Medicine, Semmelweis University, Budapest, Hungary
• ⁵ Department of Oncology, Bács-Kiskun County Teaching Hospital, Kecskemét, Hungary
• ⁶ Department of Molecular Immunology and Toxicology, National Institute of Oncology, Budapest, Hungary
• ⁷ Department of Anatomy and Histology, University of Veterinary Medicine Budapest, Budapest, Hungary
• ⁸ Chemistry Institute, University of Debrecen, Debrecen, Hungary
• ⁹ RxTarget Ltd, Szolnok, Hungary
• ¹⁰ University of Veterinary Medicine Budapest, Budapest, Hungary
• ¹¹ Department of Deputy Chief Medical Officer II., National Public Health Center, Budapest, Hungary
• ¹² Institute of Digital Health Sciences, Semmelweis University, Budapest, Hungary
• ¹³ Syntesia Medical Communications Ltd., Budapest, Hungary
• ¹⁴ Hungarian National Cancer Registry and National Tumor Biology Laboratory, National Institute of Oncology, Budapest, Hungary
• ¹⁵ Department of Pathology, Forensic and Insurance Medicine, Semmelweis University, Budapest, Hungary
• ¹⁶ National Korányi Institute of Pulmonology, Budapest, Hungary
• ¹⁷ 1st Department of Pulmonology, National Korányi Institute of Pulmonology, Budapest, Hungary
• ¹⁸ Department of Pulmonology, Albert Szent-Györgyi Medical Centre, University of Szeged, Szeged, Hungary
• ¹⁹ Pulmonology Hospital Törökbálint, Department of Pulmonology, Törökbálint, Hungary
• ²⁰ Department of Pulmonology, Semmelweis University, Budapest, Hungary
• ²¹ Faculty of Medicine, Department of Obstetrics and Gynecology, University of Debrecen, Debrecen, Hungary
• ²² Fejér County Szent György, University Teaching Hospital, Székesfehérvár, Hungary
• ²³ Department of Oncotherapy, University of Szeged, Szeged, Hungary
• ²⁴ Hungarian Central Statistical Office, Department of Population Statistics, Budapest, Hungary
• ²⁵ Center for Health Technology Assessment, Semmelweis University, Budapest, Hungary
• ²⁶ Syreon Research Institute, Budapest, Hungary

Background The nationwide HUN-CONCORD study examined cancer incidence and mortality rates in Hungary from 2011 to 2019. Methods Using data from the National Health Insurance Fund (NHIF) and Central Statistical Office (CSO), our retrospective study analyzed newly diagnosed malignancies between Jan 1, 2011, and Dec 31, 2019. Age-standardized incidence and mortality rates were calculated for all and for different tumor types using both the 1976 and 2013 European Standard Populations (ESP). Findings The number of newly diagnosed cancer cases decreased from 60,554 to 56,675 between 2011–2019. Age-standardized incidence rates were much lower in 2018, than previously estimated (475.5 vs. 580.5/100,000 person-years [PYs] in males and 383.6 vs. 438.5/100,000 PYs in females; ESP 1976). All-site cancer incidence showed a mean annual decrease of 1.9% (95% CI: 2.4%-1.4%) in men and 1.0% (95% CI:1.42%-0.66%) in women, parallel to mortality trends (-1.6% in males and -0.6% in females; ESP 2013). In 2018, the highest age-standardized incidence rates were found for lung (88.3), colorectal (82.2), and prostate cancer (62.3) in men, and breast (104.6), lung (47.7), and colorectal cancer (45.8) in women. The most significant decreases in incidence rates were observed for stomach (4.7%), laryngeal (4.4%), and gallbladder cancers (3.5%), with parallel decreases in mortality rates (3.9%, 2.7% and 3.2%, respectively). Interpretation We found a lower incidence of newly diagnosed cancer cases for Hungary compared to previous estimates, and decreasing trends in cancer incidence and mortality, in line with global findings and the declining prevalence of smoking.